Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system

The significance of tumor-associated proteolysis as reflected by parameters of the urokinase-type plasminogen activator (uPA) system for prognosis in cancer patients has been proposed because of evidence for its central role in basic mechanisms of invasion and metastasis. The aim of the present stud...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical oncology 1995-08, Vol.13 (8), p.2084-2093
Hauptverfasser: HEISS, M. M, BABIC, R, ALLGAYER, H, GRUETZNER, K. U, JAUCH, K.-W, LOEHRS, U, SCHILDBERG, F. W
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2093
container_issue 8
container_start_page 2084
container_title Journal of clinical oncology
container_volume 13
creator HEISS, M. M
BABIC, R
ALLGAYER, H
GRUETZNER, K. U
JAUCH, K.-W
LOEHRS, U
SCHILDBERG, F. W
description The significance of tumor-associated proteolysis as reflected by parameters of the urokinase-type plasminogen activator (uPA) system for prognosis in cancer patients has been proposed because of evidence for its central role in basic mechanisms of invasion and metastasis. The aim of the present study was to evaluate whether the expression of the uPA parameters might be of clinical value in gastric cancer as a tumor/biologically defined risk factor. In a consecutive series of 203 patients resected for primary gastric cancer, the expression of uPA, uPA-receptor (uPA-R), plasminogen activator inhibitor (PAI)-1, and PAI-2 was determined immunohistochemically. The results were classified semiquantitatively (0 to 3). Patients were followed-up prospectively for a median of 31 months (range, 9 to 56 months). Disease-free and overall survival were analyzed according to Kaplan-Meier and with univariate and multivariate Cox analyses in relation to conventional prognostic factors. Univariate analyses revealed a highly significant inverse correlation of uPA, uPA-R, and PAI-1 expression with survival time (P = .0008, P = .0002, and P = .0002, respectively), whereas PAI-2 demonstrated only a weak correlation. In multivariate analyses, PAI-1 was an independent and strong prognostic factor (P = .005; relative risk, 1.47 per staining degree; 95% confidence interval [CI], 1.31 to 1.64). In pT1/2 tumors and in Laurén's diffuse and mixed types, uPA, uPA-R, and PAI-1 added significant prognostic information. PAI-1 was also associated with survival in the subgroup of lymph node-positive patients. PAI-1, uPA, and uPA-R are new functional risk factors reflecting clinical prognosis. In particular, PAI-1 is a new independent variable for the identification of patients at high risk after tumor resection. Our results support the hypothesis that the uPA system probably is of general importance for prognosis of patients with malignant disease, indicating an individual tumor's capacity for invasion and metastasis.
doi_str_mv 10.1200/JCO.1995.13.8.2084
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77435931</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>77435931</sourcerecordid><originalsourceid>FETCH-LOGICAL-c358t-d0e1b0aac6c7a28b7d5951aaf9773edb4dbda29c4a3215dbc611cb3015db43873</originalsourceid><addsrcrecordid>eNpFkc9u1DAQxi0EKtvCCyAh-YC4JfhPHCfc0AoKqFIvReJmTRxn121iL56kVd6DB8ZLV-1pZjTf_Maej5B3nJVcMPbp5_a65G2rSi7LphSsqV6QDVdCF1or9ZJsmJai4I38_ZqcI94yxqtGqjNypmtZKyU25O_NMsVUAGK0HmbX00OKs4vjih4phP_1LsRcfabBPdBhCXb2McBIk8c7OoCdY0LqA90BzslbaiFYl2jvBh8ysFvpvHd0SfHOB0BXzOvB0cMIOPkQdy7QjPD3kDEUV5zd9Ia8GmBE9_YUL8ivb19vtt-Lq-vLH9svV4WVqpmLnjneMQBbWw2i6XSvWsUBhlZr6fqu6rseRGsrkIKrvrM157aT7JhXstHygnx85OY__lkczmbyaN04QnBxQaN1JVUreRaKR6FNETG5wRySnyCthjNztMJkK8zRCsOlaczRijz0_kRfusn1TyOn2-f-h1Mf0MI4pHw2j08yWfOmEeL5kXu_2z_45AxOMI4ZKsytjc_7_gFQLaOT</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77435931</pqid></control><display><type>article</type><title>Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system</title><source>MEDLINE</source><source>American Society of Clinical Oncology Online Journals</source><source>Journals@Ovid Complete</source><creator>HEISS, M. M ; BABIC, R ; ALLGAYER, H ; GRUETZNER, K. U ; JAUCH, K.-W ; LOEHRS, U ; SCHILDBERG, F. W</creator><creatorcontrib>HEISS, M. M ; BABIC, R ; ALLGAYER, H ; GRUETZNER, K. U ; JAUCH, K.-W ; LOEHRS, U ; SCHILDBERG, F. W</creatorcontrib><description>The significance of tumor-associated proteolysis as reflected by parameters of the urokinase-type plasminogen activator (uPA) system for prognosis in cancer patients has been proposed because of evidence for its central role in basic mechanisms of invasion and metastasis. The aim of the present study was to evaluate whether the expression of the uPA parameters might be of clinical value in gastric cancer as a tumor/biologically defined risk factor. In a consecutive series of 203 patients resected for primary gastric cancer, the expression of uPA, uPA-receptor (uPA-R), plasminogen activator inhibitor (PAI)-1, and PAI-2 was determined immunohistochemically. The results were classified semiquantitatively (0 to 3). Patients were followed-up prospectively for a median of 31 months (range, 9 to 56 months). Disease-free and overall survival were analyzed according to Kaplan-Meier and with univariate and multivariate Cox analyses in relation to conventional prognostic factors. Univariate analyses revealed a highly significant inverse correlation of uPA, uPA-R, and PAI-1 expression with survival time (P = .0008, P = .0002, and P = .0002, respectively), whereas PAI-2 demonstrated only a weak correlation. In multivariate analyses, PAI-1 was an independent and strong prognostic factor (P = .005; relative risk, 1.47 per staining degree; 95% confidence interval [CI], 1.31 to 1.64). In pT1/2 tumors and in Laurén's diffuse and mixed types, uPA, uPA-R, and PAI-1 added significant prognostic information. PAI-1 was also associated with survival in the subgroup of lymph node-positive patients. PAI-1, uPA, and uPA-R are new functional risk factors reflecting clinical prognosis. In particular, PAI-1 is a new independent variable for the identification of patients at high risk after tumor resection. Our results support the hypothesis that the uPA system probably is of general importance for prognosis of patients with malignant disease, indicating an individual tumor's capacity for invasion and metastasis.</description><identifier>ISSN: 0732-183X</identifier><identifier>EISSN: 1527-7755</identifier><identifier>DOI: 10.1200/JCO.1995.13.8.2084</identifier><identifier>PMID: 7636552</identifier><language>eng</language><publisher>Baltimore, MD: American Society of Clinical Oncology</publisher><subject>Adult ; Aged ; Biological and medical sciences ; Disease-Free Survival ; Female ; Follow-Up Studies ; Gastroenterology. Liver. Pancreas. Abdomen ; Humans ; Immunohistochemistry ; Male ; Medical sciences ; Middle Aged ; Multivariate Analysis ; Plasminogen Activator Inhibitor 1 - metabolism ; Plasminogen Activator Inhibitor 2 - metabolism ; Prognosis ; Prospective Studies ; Proteins - metabolism ; Receptors, Cell Surface - metabolism ; Receptors, Urokinase Plasminogen Activator ; Regression Analysis ; Risk Factors ; Stomach Neoplasms - metabolism ; Stomach Neoplasms - mortality ; Stomach Neoplasms - physiopathology ; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus ; Survival Rate ; Tumors ; Urokinase-Type Plasminogen Activator - metabolism</subject><ispartof>Journal of clinical oncology, 1995-08, Vol.13 (8), p.2084-2093</ispartof><rights>1995 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c358t-d0e1b0aac6c7a28b7d5951aaf9773edb4dbda29c4a3215dbc611cb3015db43873</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3716,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=3618822$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7636552$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HEISS, M. M</creatorcontrib><creatorcontrib>BABIC, R</creatorcontrib><creatorcontrib>ALLGAYER, H</creatorcontrib><creatorcontrib>GRUETZNER, K. U</creatorcontrib><creatorcontrib>JAUCH, K.-W</creatorcontrib><creatorcontrib>LOEHRS, U</creatorcontrib><creatorcontrib>SCHILDBERG, F. W</creatorcontrib><title>Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system</title><title>Journal of clinical oncology</title><addtitle>J Clin Oncol</addtitle><description>The significance of tumor-associated proteolysis as reflected by parameters of the urokinase-type plasminogen activator (uPA) system for prognosis in cancer patients has been proposed because of evidence for its central role in basic mechanisms of invasion and metastasis. The aim of the present study was to evaluate whether the expression of the uPA parameters might be of clinical value in gastric cancer as a tumor/biologically defined risk factor. In a consecutive series of 203 patients resected for primary gastric cancer, the expression of uPA, uPA-receptor (uPA-R), plasminogen activator inhibitor (PAI)-1, and PAI-2 was determined immunohistochemically. The results were classified semiquantitatively (0 to 3). Patients were followed-up prospectively for a median of 31 months (range, 9 to 56 months). Disease-free and overall survival were analyzed according to Kaplan-Meier and with univariate and multivariate Cox analyses in relation to conventional prognostic factors. Univariate analyses revealed a highly significant inverse correlation of uPA, uPA-R, and PAI-1 expression with survival time (P = .0008, P = .0002, and P = .0002, respectively), whereas PAI-2 demonstrated only a weak correlation. In multivariate analyses, PAI-1 was an independent and strong prognostic factor (P = .005; relative risk, 1.47 per staining degree; 95% confidence interval [CI], 1.31 to 1.64). In pT1/2 tumors and in Laurén's diffuse and mixed types, uPA, uPA-R, and PAI-1 added significant prognostic information. PAI-1 was also associated with survival in the subgroup of lymph node-positive patients. PAI-1, uPA, and uPA-R are new functional risk factors reflecting clinical prognosis. In particular, PAI-1 is a new independent variable for the identification of patients at high risk after tumor resection. Our results support the hypothesis that the uPA system probably is of general importance for prognosis of patients with malignant disease, indicating an individual tumor's capacity for invasion and metastasis.</description><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Plasminogen Activator Inhibitor 1 - metabolism</subject><subject>Plasminogen Activator Inhibitor 2 - metabolism</subject><subject>Prognosis</subject><subject>Prospective Studies</subject><subject>Proteins - metabolism</subject><subject>Receptors, Cell Surface - metabolism</subject><subject>Receptors, Urokinase Plasminogen Activator</subject><subject>Regression Analysis</subject><subject>Risk Factors</subject><subject>Stomach Neoplasms - metabolism</subject><subject>Stomach Neoplasms - mortality</subject><subject>Stomach Neoplasms - physiopathology</subject><subject>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</subject><subject>Survival Rate</subject><subject>Tumors</subject><subject>Urokinase-Type Plasminogen Activator - metabolism</subject><issn>0732-183X</issn><issn>1527-7755</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkc9u1DAQxi0EKtvCCyAh-YC4JfhPHCfc0AoKqFIvReJmTRxn121iL56kVd6DB8ZLV-1pZjTf_Maej5B3nJVcMPbp5_a65G2rSi7LphSsqV6QDVdCF1or9ZJsmJai4I38_ZqcI94yxqtGqjNypmtZKyU25O_NMsVUAGK0HmbX00OKs4vjih4phP_1LsRcfabBPdBhCXb2McBIk8c7OoCdY0LqA90BzslbaiFYl2jvBh8ysFvpvHd0SfHOB0BXzOvB0cMIOPkQdy7QjPD3kDEUV5zd9Ia8GmBE9_YUL8ivb19vtt-Lq-vLH9svV4WVqpmLnjneMQBbWw2i6XSvWsUBhlZr6fqu6rseRGsrkIKrvrM157aT7JhXstHygnx85OY__lkczmbyaN04QnBxQaN1JVUreRaKR6FNETG5wRySnyCthjNztMJkK8zRCsOlaczRijz0_kRfusn1TyOn2-f-h1Mf0MI4pHw2j08yWfOmEeL5kXu_2z_45AxOMI4ZKsytjc_7_gFQLaOT</recordid><startdate>19950801</startdate><enddate>19950801</enddate><creator>HEISS, M. M</creator><creator>BABIC, R</creator><creator>ALLGAYER, H</creator><creator>GRUETZNER, K. U</creator><creator>JAUCH, K.-W</creator><creator>LOEHRS, U</creator><creator>SCHILDBERG, F. W</creator><general>American Society of Clinical Oncology</general><general>Lippincott Williams &amp; Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19950801</creationdate><title>Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system</title><author>HEISS, M. M ; BABIC, R ; ALLGAYER, H ; GRUETZNER, K. U ; JAUCH, K.-W ; LOEHRS, U ; SCHILDBERG, F. W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c358t-d0e1b0aac6c7a28b7d5951aaf9773edb4dbda29c4a3215dbc611cb3015db43873</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Plasminogen Activator Inhibitor 1 - metabolism</topic><topic>Plasminogen Activator Inhibitor 2 - metabolism</topic><topic>Prognosis</topic><topic>Prospective Studies</topic><topic>Proteins - metabolism</topic><topic>Receptors, Cell Surface - metabolism</topic><topic>Receptors, Urokinase Plasminogen Activator</topic><topic>Regression Analysis</topic><topic>Risk Factors</topic><topic>Stomach Neoplasms - metabolism</topic><topic>Stomach Neoplasms - mortality</topic><topic>Stomach Neoplasms - physiopathology</topic><topic>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</topic><topic>Survival Rate</topic><topic>Tumors</topic><topic>Urokinase-Type Plasminogen Activator - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HEISS, M. M</creatorcontrib><creatorcontrib>BABIC, R</creatorcontrib><creatorcontrib>ALLGAYER, H</creatorcontrib><creatorcontrib>GRUETZNER, K. U</creatorcontrib><creatorcontrib>JAUCH, K.-W</creatorcontrib><creatorcontrib>LOEHRS, U</creatorcontrib><creatorcontrib>SCHILDBERG, F. W</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HEISS, M. M</au><au>BABIC, R</au><au>ALLGAYER, H</au><au>GRUETZNER, K. U</au><au>JAUCH, K.-W</au><au>LOEHRS, U</au><au>SCHILDBERG, F. W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system</atitle><jtitle>Journal of clinical oncology</jtitle><addtitle>J Clin Oncol</addtitle><date>1995-08-01</date><risdate>1995</risdate><volume>13</volume><issue>8</issue><spage>2084</spage><epage>2093</epage><pages>2084-2093</pages><issn>0732-183X</issn><eissn>1527-7755</eissn><abstract>The significance of tumor-associated proteolysis as reflected by parameters of the urokinase-type plasminogen activator (uPA) system for prognosis in cancer patients has been proposed because of evidence for its central role in basic mechanisms of invasion and metastasis. The aim of the present study was to evaluate whether the expression of the uPA parameters might be of clinical value in gastric cancer as a tumor/biologically defined risk factor. In a consecutive series of 203 patients resected for primary gastric cancer, the expression of uPA, uPA-receptor (uPA-R), plasminogen activator inhibitor (PAI)-1, and PAI-2 was determined immunohistochemically. The results were classified semiquantitatively (0 to 3). Patients were followed-up prospectively for a median of 31 months (range, 9 to 56 months). Disease-free and overall survival were analyzed according to Kaplan-Meier and with univariate and multivariate Cox analyses in relation to conventional prognostic factors. Univariate analyses revealed a highly significant inverse correlation of uPA, uPA-R, and PAI-1 expression with survival time (P = .0008, P = .0002, and P = .0002, respectively), whereas PAI-2 demonstrated only a weak correlation. In multivariate analyses, PAI-1 was an independent and strong prognostic factor (P = .005; relative risk, 1.47 per staining degree; 95% confidence interval [CI], 1.31 to 1.64). In pT1/2 tumors and in Laurén's diffuse and mixed types, uPA, uPA-R, and PAI-1 added significant prognostic information. PAI-1 was also associated with survival in the subgroup of lymph node-positive patients. PAI-1, uPA, and uPA-R are new functional risk factors reflecting clinical prognosis. In particular, PAI-1 is a new independent variable for the identification of patients at high risk after tumor resection. Our results support the hypothesis that the uPA system probably is of general importance for prognosis of patients with malignant disease, indicating an individual tumor's capacity for invasion and metastasis.</abstract><cop>Baltimore, MD</cop><pub>American Society of Clinical Oncology</pub><pmid>7636552</pmid><doi>10.1200/JCO.1995.13.8.2084</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0732-183X
ispartof Journal of clinical oncology, 1995-08, Vol.13 (8), p.2084-2093
issn 0732-183X
1527-7755
language eng
recordid cdi_proquest_miscellaneous_77435931
source MEDLINE; American Society of Clinical Oncology Online Journals; Journals@Ovid Complete
subjects Adult
Aged
Biological and medical sciences
Disease-Free Survival
Female
Follow-Up Studies
Gastroenterology. Liver. Pancreas. Abdomen
Humans
Immunohistochemistry
Male
Medical sciences
Middle Aged
Multivariate Analysis
Plasminogen Activator Inhibitor 1 - metabolism
Plasminogen Activator Inhibitor 2 - metabolism
Prognosis
Prospective Studies
Proteins - metabolism
Receptors, Cell Surface - metabolism
Receptors, Urokinase Plasminogen Activator
Regression Analysis
Risk Factors
Stomach Neoplasms - metabolism
Stomach Neoplasms - mortality
Stomach Neoplasms - physiopathology
Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
Survival Rate
Tumors
Urokinase-Type Plasminogen Activator - metabolism
title Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T10%3A48%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tumor-associated%20proteolysis%20and%20prognosis:%20new%20functional%20risk%20factors%20in%20gastric%20cancer%20defined%20by%20the%20urokinase-type%20plasminogen%20activator%20system&rft.jtitle=Journal%20of%20clinical%20oncology&rft.au=HEISS,%20M.%20M&rft.date=1995-08-01&rft.volume=13&rft.issue=8&rft.spage=2084&rft.epage=2093&rft.pages=2084-2093&rft.issn=0732-183X&rft.eissn=1527-7755&rft_id=info:doi/10.1200/JCO.1995.13.8.2084&rft_dat=%3Cproquest_cross%3E77435931%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77435931&rft_id=info:pmid/7636552&rfr_iscdi=true